Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
2.4 USD -8.05% Intraday chart for Allogene Therapeutics, Inc. +7.62% -25.23%
06-20 Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma CI
06-10 Allogene Therapeutics, Inc. Announces Executive Changes CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allogene Therapeutics, Inc. Announces Executive Changes
CI
Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President
CI
Allogene Therapeutics Finance Chief Eric Schmidt to Step Down
MT
Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023
CI
Allogene Therapeutics, Inc. Appoints Timothy Moore as Executive Vice President and Chief Technical Officer, Effective April 24, 2023
CI
Allogene Therapeutics, Inc., Announces Resignation of Alison Moore as Chief Technical Officer, Effective April 28, 2023
CI
Allogene Therapeutics, Inc. Announces Resignation of Rafael G. Amado as Executive Vice President of Research and Development
CI
Allogene Appoints Zachary J. Roberts as Executive Vice President of Research & Development
CI
Insider Sell: Allogene Therapeutics
MT
Allogene Therapeutics, Inc. Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
CI
Insider Sell: Allogene Therapeutics
MT
Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective May 2, 2022
CI
Insider Buy: Allogene Therapeutics
MT
Insider Buy: Allogene Therapeutics
MT
Allogene Therapeutics Appoints Jae Park to Its Scientific Advisory Board
CI
Insider Sell: Allogene Therapeutics
MT
Insider Sell: Allogene Therapeutics
MT
Allogene Therapeutics, Inc. Announces Executive Appointments
CI
Allogene Overland Biopharm, a Joint Venture Created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. Appoints Shuyuan Yao as Chief Executive Officer
CI
Gracell Biotechnologies : Names Jenny Ni Chief Technology Officer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. News Allogene Therapeutics, Inc.
  5. Insiders